Education
About Us
Working with TipRanks
Follow Us
Nanobiotix (NBTX)
NASDAQ:NBTX
NBTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.76 - $7.51
Previous CloseN/A
Volume23.08K
Average Volume (3M)9.59K
Market Cap
$153.45M
Enterprise ValueN/A
Total Cash (Recent Filing)€75.28M
Total Debt (Recent Filing)€50.56M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Mar 13, 2025EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding47,133,327
10 Day Avg. Volume11,552
30 Day Avg. Volume9,587
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.50Price Target Upside13.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Nanobiotix News
PremiumCompany Announcements
Nanobiotix Releases Voting Rights and Shares Capital Update
PremiumCompany Announcements
Nanobiotix to Engage Investors at Upcoming Conferences
PremiumCompany Announcements
Nanobiotix Begins Phase 2 Trial for Novel Lung Cancer Treatment
PremiumCompany Announcements
Nanobiotix Updates Voting Rights and Share Capital Information---
Bulls Say, Bears Say
Bulls Say
Clinical CollaborationNBTX is collaborating with MD Anderson Cancer Center to explore the potential of NBTXR3 in a range of additional tumor types, including locally advanced or borderline resectable pancreatic cancer, inoperable locoregionally recurrent NSCLC, esophageal cancer, and other tumors.
Strategic PartnershipsThe management team highlighted a well-defined pathway for the development of nanoprimers and potential partnerships with several material transfer agreements already in progress.
Bears Say
Financial Stability ConcernsInvestor focus will largely remain on the company's cash runway and the ongoing Phase III NANORAY-312 study, indicating concerns about financial stability.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
12.03% Other Institutional Investors
87.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NBTX FAQ
What was Nanobiotix’s price range in the past 12 months?
Nanobiotix lowest stock price was $2.76 and its highest was $7.51 in the past 12 months.
What is Nanobiotix’s market cap?
Nanobiotix’s market cap is $153.45M.
When is Nanobiotix’s upcoming earnings report date?
Nanobiotix’s upcoming earnings report date is Mar 13, 2025 which is today.
How were Nanobiotix’s earnings last quarter?
Currently, no data Available
Is Nanobiotix overvalued?
According to Wall Street analysts Nanobiotix’s price is currently Undervalued.
Does Nanobiotix pay dividends?
Nanobiotix does not currently pay dividends.
What is Nanobiotix’s EPS estimate?
Nanobiotix’s EPS estimate is -0.57.
How many shares outstanding does Nanobiotix have?
Nanobiotix has 47,133,327 shares outstanding.
What happened to Nanobiotix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix?
Currently, no hedge funds are holding shares in NBTX
---
Nanobiotix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (13.27% Upside)
$3.50 (13.27% Upside)
Hedge Fund Trend
Decreased
By 289.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.37%
12-Months-Change
Fundamentals
Return on Equity
2152.93%
Trailing 12-Months
Asset Growth
110.74%
Trailing 12-Months
Company Description
Nanobiotix
Nanobiotix SA is a late-stage clinical company engaged in developing and selling nanomedicine for the treatment of cancer. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. The company's products include NBTXR3, a preclinical research program for cancer immunotherapies.
---
NBTX Stock 12 Month Forecast
Average Price Target
$3.50
▲(13.27% Upside)
Technical Analysis
TG Therapeutics
―
Immunic
―
Brainstorm Cell Therapeutics
―
Cellectis SA
―
ADC Therapeutics
―
Best Analysts Covering NBTX
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-38.11%
reiterated a buy rating 3 months ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -38.11% per trade.
---